Laborie Medical Technologies, a diagnostic and therapeutic medical technology company, today announced an investment in Novocuff, an early-stage medical technology company headquartered in Mountain View, California. The company's mission is to transform the standard of care and improve pregnancy outcomes for women and their newborns.
Founded in 2021, Novocuff has developed a medical device aimed at stabilizing and closing the cervix to retain amniotic fluid and sustain cervical length, with the goal of extending pregnancy. The company is pursuing a novel approach to provide a solution to treat Preterm Premature Rupture of Membranes (PPROM) and cervical shortening, major contributors to preterm birth that impact millions of families worldwide each year. Preterm birth (before 37 weeks gestational age) is a leading cause of infant death globally.
"For the last 30 years, our mission has been to help every mother and every newborn go home healthy," said Nikki Bruce, vice president and general manager of Laborie's OB Business Unit. "We believe Novocuff's device has the potential to address pregnancy complications that often result in preterm birth, and our investment underscores our commitment to improving patient outcomes."
